低分子肝素加阿托伐他汀治疗不稳定型心绞痛疗效分析被引量：3

Effect of Fraxiparin Combined with Atorvastatin on Unstable Angina Pectoris

下载PDF

导出

摘要目的观察低分子肝素联合阿托伐他汀治疗不稳定型心绞痛患者的疗效。方法62例UAP患者,随机分为对照组和治疗组,对照组采用硝酸酯类等治疗,治疗组加用低分子肝素和阿托伐他汀,比较两组治疗效果。结果治疗组总有效率90.3%,明显高于对照组的71.0%(P<0.05),且无明显的副作用。结论低分子肝素联合阿托伐他汀是一组有效、安全的治疗不稳定心绞痛的药物。 Objective To investigate the effect of fraxiparin combined with atorvastatin on unstable angina pectoris. Methods 62 patients with UAP were divided into control group and treatment group who took fraxiparin and atorvastatin besides treatments as same as in control group. The effects of two groups were analyzed. Results The total effect rate in treatment group was better than that in control group （90.3%vs71.0%, P 〈 0.05）. Conclusion Fraxiparin combined with atorvastatin is effective and safe in the treatment of UAP.

作者李凤珠

机构地区湖南省郴州市第一人民医院急诊科

出处《中国现代医生》 2008年第13期99-99,101,共2页 China Modern Doctor

关键词不稳定型心绞痛低分子肝素阿托伐他汀疗效 Unstable angina pectoris Fraxiparin Atorvastatin Curative effect

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1刘国仗,胡大一,陶萍,诸骏仁,郭林妮,郭静萱,游凯.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11. 被引量：1440
2宁吉存.低分子肝素对顽固性不稳定型心绞痛的治疗作用[J].实用医药杂志,2003,20(2):99-100. 被引量：9
3刘建敏,陈丽.不同剂量尿激酶及肝素对不稳定性心绞痛的疗效观察[J].实用心脑肺血管病杂志,2005,13(5):264-267. 被引量：15
4[4]Arca M,Gaspardone A.Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events[J].Drugs,2007,67(Suppl 1):29-42.

二级参考文献18

1国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(1):75-75.
2Bar FW Veiheugt, FW, Col J,et al. Thrombolysis in patients with unstable angina impioves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter randomized, placebo-controlled clinical trial with anistreplase. Circulation. 1992,86:131-137.
3TIMI Ⅲ B Investigators. Effects of tissue plasminogen activeator and a comparei son of ealy invasive and conservat ive strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI Ⅲ Btrial. Circulation. 1994,89 : 1545 - 1556.
4Leschke M, Schoeble FC, Mecklehbeck W,et al. Long-term intermittent uiokinase therapy in pat ients with end-stage coronary artery disease and refractory andgina pectoris: A randomized dose-response trial. J Am Coll Cardiol. 1996,27:575 -584.
5Collaborative Research Group of Nattional Project( 85-915-02-01 ). A clinical study on thrombolysis with intravenous urokinase in 1138 cases of acute myocardial infarction. Chin J Cardiol. 1996,24:169 -173.
6Ji-lin chen randomized clinical trial of urokinase versus heparin in unstable angina. Jourmal of Thrombos is and Thrombos is and Thrombolysis. 1999,8:223 - 226.
7Braunwald E, Antman EM, Beasley TW, et al. ACC/AHA quideline update for the managemeat of paients with unstable angina and nonSTSegment elevation myocardial infaet ion-2002 ; sununary ariele; a report of the American College of Cardioiogy/American Heart Association Task Force On Practice Guidelines( cofnmittee on the management of Unstable Angina). Circulation. 2002,106:1893 - 1900.
8Theroux, P, Lidon R. Unstable angina: pathogensis,diagnosis and treatment. Curr Probl Cardiol,1993,18:159
9Kirkeboen KA.Unstable angina pectoris pathogenesis,treatment and prognosis.Tidsskr Nor Laegforen, 1995,115(27):3376
10Bresnahan DR,Danis JL,Holmes dr jr,et al.Angiographic occurrence and clinical correlates of intraluminal coronary artery thrombus:role of unstable angina. J Am Coll Cardiol,1985,45(9):285